SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

Pharmaceutical

SciClone Pharmaceuticals Inc

SciClone Pharmaceuticals Inc's headquarters in Foster City, CA, United States

宏 赵

Shidong Zhang

Peter Shao

岩松（Phil） 常

Cecile Pan

Bokang Zhou

The Leadership Team at SciClone Pharmaceuticals Inc. is responsible for setting the strategic direction and operational priorities of the company. Comprising key executives from various disciplines—medical, technical operations, marketing, finance, and oncology management—they collaborate to drive innovation, optimize product offerings, and ensure compliance with regulatory standards in both the Chinese market and internationally. Their collective expertise guides the development of therapies and strengthens SciClone's position within the global pharmaceutical landscape.

Leadership Team

The Medical Affairs and Regulatory Compliance team at SciClone Pharmaceuticals Inc. plays a crucial role in ensuring that the company's products comply with regulatory standards and guidelines in various markets, particularly in China. This team is responsible for facilitating communication between clinical development and marketing, providing scientific support for product information, and overseeing regulatory submissions to ensure the safe and effective use of therapies. Additionally, they engage with healthcare professionals and regulatory bodies to uphold the integrity of the company's product portfolio.

Medical Affairs and Regulatory Compliance

The Business Development and Strategy team at SciClone Pharmaceuticals Inc is responsible for identifying growth opportunities, forming strategic partnerships, and developing plans to expand the company's footprint in the pharmaceutical market, particularly in China. They analyze market trends, assess competitive landscapes, and evaluate potential collaborations to drive the company's product portfolio, including ZADAXIN and other therapies, ensuring alignment with corporate goals and maximizing stakeholder value.

SciClone Pharmaceuticals Inc

Org chart

Teams

Leadership Team

Medical Affairs and Regulatory Compliance

Business Development and Strategy

Offices

SciClone Pharmaceuticals Inc

Org chart

Teams

Leadership Team

Medical Affairs and Regulatory Compliance

Business Development and Strategy

Offices

Related companies